CDT Equity (CDT) Shares Outstanding (2021 - 2026)
CDT Equity's (CDT) quarterly Shares Outstanding (Entity) came in at $73046.0 in Q1 2026, up 56089.23% YoY from N/an in Q1 2025, and up 2093.57% on a QoQ basis from $3330.0 in Q4 2025.
CDT Equity (CDT) Shares Outstanding (2021 - 2026) Analysis & Trends
CDT Equity (CDT) has 6 years of Shares Outstanding (Entity) data on file, last reported at $73046.0 in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 56089.23% year-over-year to $73046.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73046.0 (up 56089.23% YoY) and the FY2025 annual result came in at $3330.0, up 11382.76% from the prior year.
- Shares Outstanding (Entity) improved to $73046.0 in Q1 2026, from $3330.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $73046.0 in Q1 2026 to a low of $1.0 in Q2 2023.
- A 5-year average of $4670.6 and a median of $25.0 in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) slumped 80.0% — and 2026, when it jumped 56089.23%.
- Tracing CDT's Shares Outstanding (Entity) over 5 years: stood at $4.0 in 2022, then jumped by 525.0% to $25.0 in 2023, then gained by 16.0% to $29.0 in 2024, then jumped by 11382.76% to $3330.0 in 2025, then surged by 2093.57% to $73046.0 in 2026.
- The last three Shares Outstanding (Entity) figures came in at $73046.0 (Q1 2026), $3330.0 (Q4 2025), and $2163.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 532,999.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73,046.00 |
| Mar 31, 2026 | 73,046.00 |
| Dec 31, 2025 | 3,330.00 |
| Sep 30, 2025 | 2,163.00 |
| Jun 30, 2025 | 552.00 |
| Mar 31, 2025 | 130.00 |
| Dec 31, 2024 | 29.00 |
| Sep 30, 2024 | 29.00 |
| Jun 30, 2024 | 25.00 |
| Mar 31, 2024 | 25.00 |
| Dec 31, 2023 | 22.00 |
| Sep 30, 2023 | 22.00 |
| Jun 30, 2023 | 1.00 |
| Mar 31, 2023 | 2.00 |
| Dec 31, 2022 | 4.00 |
| Sep 30, 2022 | 5.00 |
| Jun 30, 2022 | 5.00 |
| Mar 31, 2022 | 3.00 |
| Dec 31, 2021 | 1.00 |